Adjuvant docetaxel for high-risk, node-negative breast cancer

Area of Science:

• Oncology
• Clinical Trials
• Breast Cancer Therapeutics

Background:

• Docetaxel, doxorubicin, and cyclophosphamide (TAC) regimen demonstrated superiority over fluorouracil, doxorubicin, and cyclophosphamide (FAC) in node-positive breast cancer.
• The efficacy of taxane-based regimens in node-negative breast cancer remained undetermined.

Purpose of the Study:

• To evaluate the effectiveness of TAC compared to FAC as adjuvant therapy for node-negative breast cancer patients with high-risk factors.
• To assess disease-free survival, overall survival, and toxicity profiles of both treatment regimens.

Main Methods:

• A randomized trial involving 1060 women with node-negative breast cancer and at least one high-risk factor.
• Patients were assigned to receive either TAC or FAC every 3 weeks for six cycles post-surgery.
• Primary endpoint was disease-free survival after a minimum of 5 years of follow-up.

Main Results:

• At a median follow-up of 77 months, TAC demonstrated a significantly higher disease-free survival rate (87.8%) compared to FAC (81.8%), translating to a 32% reduction in recurrence risk (P=0.01).
• No significant difference in overall survival was observed between the two groups (TAC: 95.2%; FAC: 93.5%).
• Grade 3 or 4 adverse events were more frequent with TAC (28.2%) than FAC (17.0%), but toxicity was manageable with granulocyte colony-stimulating factor prophylaxis.

Conclusions:

• Adjuvant TAC therapy significantly improved disease-free survival in women with high-risk, node-negative breast cancer compared to adjuvant FAC.
• The findings support the use of TAC in this patient population, with careful monitoring for toxicity.